S100A4 AS A MARKER OF TREATMENT WITH SPIRONOLACTONE, PIOGLITAZONE AND METFORMIN

摘要

The invention relates to the in vitro use of a ligand specifically binding to S100A4, such as antibody for identifying the response to treatment with spironolactone, pioglitazone and metformin, such as in PCOS patients. The invention further relates to an in vitro method for monitoring responsiveness of a subject to a treatment with spironolactone, pioglitazone and metformin, the method comprising: determining the concentration of S100A4 in a body sample obtained from the subject prior or at the onset of the treatment, determining the concentration of S100A4 in said body sample obtained from the subject during said treatment, wherein a decrease of S100A4 concentration compared to the concentration prior to or at the onset is indicative for an effective treatment.